Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma (ABUS)
:ABUS
ABUS Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ABUS Stock 12 Month Forecast
Average Price Target
$5.00
▲(39.66%Upside)
| Highest Price Target$5.00 | Average Price Target$5.00 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$3.5
Hold
-2.23%
Downside
Reiterated
05/29/25
Arbutus Biopharma's overall stock score is driven by significant financial challenges, with negative profitability and cash flow issues. Technical analysis suggests a neutral short-term outlook, while valuation metrics highlight concerns about overvaluation. Positive developments in HBV treatment are promising but offset by executive turnover and legal uncertainties.
Citizens JMP
$5
Buy
39.66%
Upside
Reiterated
03/31/25
H.C. Wainwright
$5
Buy
39.66%
Upside
Reiterated
01/21/25
Chardan Capital
$4.5→$5
Buy
39.66%
Upside
Reiterated
11/19/24
Robert W. Baird
$4
Hold
11.73%
Upside
Reiterated
11/06/24
Jefferies
$7
Buy
95.53%
Upside
Reiterated
09/04/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$3.5
Hold
-2.23%
Downside
Reiterated
05/29/25
Arbutus Biopharma's overall stock score is driven by significant financial challenges, with negative profitability and cash flow issues. Technical analysis suggests a neutral short-term outlook, while valuation metrics highlight concerns about overvaluation. Positive developments in HBV treatment are promising but offset by executive turnover and legal uncertainties.
Citizens JMP
$5
Buy
39.66%
Upside
Reiterated
03/31/25
H.C. Wainwright
$5
Buy
39.66%
Upside
Reiterated
01/21/25
Chardan Capital
$4.5→$5
Buy
39.66%
Upside
Reiterated
11/19/24
Robert W. Baird
$4
Hold
11.73%
Upside
Reiterated
11/06/24
Jefferies
$7
Buy
95.53%
Upside
Reiterated
09/04/24
Best Analysts Covering Arbutus Biopharma
1 Month
xxx
Success Rate
20/38 ratings generated profit
Average Return
-5.01%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.63% of your transactions generating a profit, with an average return of -5.01% per trade.
3 Months
xxx
Success Rate
15/34 ratings generated profit
Average Return
+0.96%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.12% of your transactions generating a profit, with an average return of +0.96% per trade.
1 Year
Success Rate
18/34 ratings generated profit
Average Return
+6.46%
reiterated a buy rating 3 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +6.46% per trade.
2 Years
xxx
Success Rate
23/34 ratings generated profit
Average Return
+19.47%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 67.65% of your transactions generating a profit, with an average return of +19.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ABUS Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
1
1
1
1
1
Buy
4
7
8
8
4
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
9
10
10
5
Each month's total comprises the sum of three months' worth of ratings.
ABUS Financial Forecast
ABUS Stock Forecast FAQ
What is ABUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Arbutus Biopharma’s 12-month average price target is 5.00.
What is ABUS’s upside potential, based on the analysts’ average price target?
Arbutus Biopharma has 39.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ABUS a Buy, Sell or Hold?
Arbutus Biopharma has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Arbutus Biopharma’s price target?
The average price target for Arbutus Biopharma is 5.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 39.66% Increase from the current price of $3.58.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 39.66% Increase from the current price of $3.58.
What do analysts say about Arbutus Biopharma?
Arbutus Biopharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of ABUS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.